SynthesisEuropean journal of medical research2025
Inhaled nitric oxide in preterm infants with respiratory disease: a systematic review and meta-analysis.
Synthesis in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundInhaled nitric oxide (iNO) has been shown to be effective in term and near-term infants with specific respiratory diseases. The effects and potential risks of iNO differ substantially in preterm infants with special pathophysiology. Specific study in this population is necessary. PURPOSE: To assess the short-term and long-term effects of iNO in preterm infants with respiratory diseases such as respiratory failure and respiratory distress syndrome.
methodsWe conducted a meta-analysis of randomized controlled trials and cohort studies comparing iNO with placebo or blank control in preterm infants with respiratory diseases.Databases including PubMed, the Cochrane Library, Scopus, and Web of Science were searched from their inception until May 2025. The primary outcomes were death before discharge, death at 36 weeks' postmenstrual age (PMA), bronchopulmonary dysplasia (BPD) and death or BPD.
resultsThirty-one trials met the inclusion criteria. iNO reduced the incidence of death or BPD (risk ratio [RR] 0.94, 95% confidence interval [CI] 0.88 to 0.99, 6 studies, 1954 infants) and BPD in the RCT subgroup (RR 0.91, 95% CI 0.84 to 0.99, 8 studies, 2196 infants).Increases of oxygenation index (Standardized mean difference (SMD) - 0.62, 95% CI - 0.81 to - 0.43, 2 studies, 441 infants) and Partial pressure of oxygen (PaO
conclusionsiNO was associated with a reduced risk of death or BPD and a probably reduction of BPD. There was no effect on other morbidities or adverse events. Data on long-term respiratory and neurodevelopment outcomes are critically needed to further evaluate NO's efficacy in preterm infants, particularly Extremely low birth weight infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.